Cormorant Asset Management, LP's Form 4 filing
Ambrx Biopharma, Inc. (AMAM) · filed Apr 17, 2023
- Accession no.
- 0000929638-23-001185
- Filed
- Apr 17, 2023, 5:46 PM ET
- Trade date
- Apr 13-17, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $25.3M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cormorant Asset Management, LPCIK 0001583977 | 10% Owner |
| Chen BihuaCIK 0001599214 | 10% Owner |
| Cormorant Global Healthcare Master Fund, LPCIK 0001618442 | 10% Owner |
| Cormorant Private Healthcare Fund III LPCIK 0001817320 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 13, 2023 | Ordinary Shares | PPurchaseAcquired | +1,193,808 | $9.16F1 | +$10,935,520.04 | 60,693,808 | Indirect | |
| Apr 14, 2023 | Ordinary Shares | PPurchaseAcquired | +841,967 | $9.96F5 | +$8,384,307.39 | 61,535,775 | Indirect | |
| Apr 17, 2023 | Ordinary Shares | PPurchaseAcquired | +562,121 | $10.67F7 | +$5,999,461.22 | 62,097,896 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the weighted average sale price of American Depository Shares ("ADS") purchased in a series of open market transactions on the transaction date at prices ranging from $8.77 to $9.50 per ADS. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ADS purchased at each price. All of these ADS were purchased by Fund III (as defined below).
Referenced by the price of 1 transaction in Table I.
- F5
Represents the weighted average sales price of ADS purchased in a series of open market transactions on the transaction date at prices ranging from $9.60 to $10.00 per ADS. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ADS purchased at each price. All of these ADS were purchased by Fund III.
Referenced by the price of 1 transaction in Table I.
- F7
Represents the weighted average sales price of ADS purchased in a series of open market transactions on the transaction date at prices ranging from $10.22 to $11.00 per ADS. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ADS purchased at each price. All of these ADS were purchased by Fund III.
Referenced by the price of 1 transaction in Table I.